CARDIOL THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.4 CAD | -3.61% |
|
-0.41% | +118.18% |
| Apr. 22 | HC Wainwright Starts Cardiol Therapeutics With Buy Rating, $9 Price Target | MT |
| Apr. 01 | Cardiol Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 164M 120M |
|---|---|---|---|---|---|
| Net income 2024 * | -26M -18.97M | Net income 2025 * | -28M -20.43M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 18.78M 13.7M | Net cash position 2025 * | 13.62M 9.94M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-6.32
x | P/E ratio 2025 * |
-6.32
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.43% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -3.61% | ||
| 1 week | -0.41% | ||
| Current month | -1.23% | ||
| 1 month | +18.81% | ||
| 3 months | +57.89% | ||
| 6 months | +163.74% | ||
| Current year | +118.18% |
1 week
2.15
2.58
1 month
1.942.82
Current year
1.132.94
1 year
0.742.94
3 years
0.616.19
5 years
0.616.27
10 years
0.618.49
| Managers | Title | Age | Since |
|---|---|---|---|
David Elsley
FOU | Founder | - | 17-01-18 |
| Director of Finance/CFO | - | 18-08-15 | |
Kelly Narine
CTO | Chief Tech/Sci/R&D Officer | - | 20-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Elsley
FOU | Founder | - | 17-01-18 |
Jennifer Chao
BRD | Director/Board Member | 54 | 22-03-14 |
Michael Willner
BRD | Director/Board Member | 57 | 21-09-06 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 2.4 | -3.61% | 42,575 |
| 24-04-23 | 2.49 | +2.05% | 74,952 |
| 24-04-22 | 2.44 | -1.21% | 68,966 |
| 24-04-19 | 2.47 | +5.56% | 163,892 |
| 24-04-18 | 2.34 | -3.11% | 44,166 |
Delayed Quote Toronto S.E., April 24, 2024 at 03:59 pm EDT
More quotes
Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.4
CAD
Average target price
4.5
CAD
Spread / Average Target
+87.50%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +118.18% | 124M | |
| +4.09% | 43.43B | |
| +47.81% | 41.69B | |
| +9.45% | 41.31B | |
| -10.92% | 27.14B | |
| +9.32% | 25.28B | |
| -24.87% | 18.47B | |
| +29.70% | 12.59B | |
| +1.28% | 12.33B | |
| +7.78% | 11.03B |
- Stock Market
- Equities
- CRDL Stock
